Patterson Companies Inc (PDCO) Return on Equity ROE from the third quarter 2025 to third quarter 2024 and annually, average high and low, overall ranking from Jan 25 2025 to Jan 27 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Patterson Companies Inc   (NASDAQ: PDCO)

Patterson Companies Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Patterson Companies Inc in the third quarter 2025?
Patterson Companies Inc achieved a return on average equity (ROE) of 14.17 % in its third quarter 2025, this is above PDCO's average return on equity of 11.31%.
Patterson Companies Inc shareholder's equity over the 12 months ending in its third quarter 2025 are valued at $977 million

ROE fell compared to the second quarter 2025, despite the net income growth of 16.76% from the second quarter 2025.

Within the Medical Equipment & Supplies industry 26 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2025 from 720 to 958.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jan 25 2025)
III. Quarter		 (Oct 26 2024)
II. Quarter		 (Jul 27 2024)
I. Quarter		 (Apr 27 2024)
IV. Quarter		 (Jan 27 2024)
III. Quarter
Y / Y Equity Change 1.83 % -8.69 % -14.28 % -10.44 % -
Y / Y Net Income Change -34.51 % -33.02 % -56.19 % -10.56 % -11.61 %
Net Income (TTM) in Millions 138 155 168 186 193
Return On Equity (TTM) 14.17 % 15.93 % 16.88 % 17.92 % 18.17 %
PDCO's Total Ranking # 958 # 720 # 635 # 0 # 699
Equity (TTM) in Millions 990 963 953 1,002 972
Seq. Equity Change 2.75 % 1.15 % -4.91 % 3.04 % -7.86 %
Seq. Net Income Change 16.76 % 95.73 % -79.63 % 40.65 % 19.42 %

Back to PDCO Management Effectiveness >> PDCO's 5 Years Annual ROE >> Compare PDCO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 27
Sector # 101
Overall # 958

Return On Equity Statistics
High Average Low
19.78 %
11.31 %
-54.82 %
(Apr 30 2022)   (Jan 23 2021)





PDCO Annual Return On Equity (Apr 27 2024)
2024		 (Apr 29 2023)
2023		 (Apr 30 2022)
2022		 (Apr 24 2021)
2021		 (Apr 25 2020)
2020
Total Equity in Millions 1,002 1,119 1,043 965 836
Y / Y Equity Change -10.44 % 7.28 % 8.08 % 15.33 % -43.5 %
Net Income in Millions 186 207 202 155 -589
Y / Y Net Income Change -10.2 % 2.42 % 30.05 % - -
Return On Equity 18.52 % 18.47 % 19.35 % 16.08 % -70.46 %

Back to PDCO Management Effectiveness >> PDCO's 5 Years Annual ROE >> Compare PDCO ROE to its Competitors




Annual Roe Comment
Despite deterioration in net income, company improved ROE to in 2024, company improved ROE to 18.52 % compared to the prior year.


More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PDCO's' Return on Equity at Yahoo Finance
PDCO's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PDCO's Competitors
Subscribers only: Roe for Patterson Companies Inc 's Suppliers
Subscribers only: Return On Equity for PDCO's Customers




Companies with similar Return On Equity at Jan 25 2025, within Healthcare Sector ROE
Semler Scientific inc   34.63 %
Medinotec Inc   34.27 %
Entrada Therapeutics Inc   34.08 %
Siga Technologies Inc  33.00 %
Abbott Laboratories  32.19 %
Hims and Hers Health Inc   31.06 %
Kewaunee Scientific Corporation  30.86 %
Collegium Pharmaceutical Inc   30.69 %
Lantheus Holdings Inc   29.48 %
Prestige Consumer Healthcare Inc   29.24 %
Agilent Technologies inc   28.56 %
Alkermes Plc   27.73 %
Lifevantage Corp  27.58 %
Engene Therapeutics Inc   27.12 %
Novartis Ag  27.06 %
Msa Safety Inc  26.71 %
Dexcom Inc   26.30 %
Inmode Ltd   25.76 %
Catalyst Pharmaceuticals Inc   25.62 %
Ge Healthcare Technologies Inc   25.59 %
Resmed Inc   25.55 %
Chemed Corporation  25.46 %
Harmony Biosciences Holdings inc   25.19 %
Mimedx Group Inc   24.31 %
Iradimed Corporation  23.60 %
Ardent Health Inc   23.33 %
Curevac N v   23.28 %
Encompass Health Corporation  23.16 %
Concentra Group Holdings Parent Inc   22.79 %
Corcept Therapeutics Inc  22.70 %

Date modified: 2026-09-08T15:11:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.